Biomarkers for acute GVHD: can we predict the unpredictable?

Area of Science:

• Hematology and Immunology
• Transplantation Medicine
• Biomarker Discovery

Background:

• Acute graft-versus-host disease (GVHD) is a significant complication following allogeneic hematopoietic cell transplantation (HCT).
• Current diagnostic and management strategies often rely on invasive tissue biopsies.
• Previous biomarker research focused on non-specific inflammatory cytokines (e.g., IL-2, TNF-α).

Purpose of the Study:

• To identify novel, noninvasive peripheral blood biomarkers for acute GVHD.
• To improve the diagnosis and management of acute GVHD, avoiding invasive procedures.
• To develop risk-adapted therapeutic approaches based on biomarker profiles.

Main Methods:

• Utilized modern proteomic methods to screen large patient sample sets.
• Investigated candidate biomarkers including cytokines, cell-surface molecules, elafin, and reg3α.
• Evaluated the predictive value of a combined biomarker panel for patient outcomes.

Main Results:

• Identified novel candidate biomarkers such as elafin and reg3α, potentially indicating end-organ injury.
• Demonstrated that a panel combining new molecules and traditional cytokines can predict outcomes in acute GVHD patients.
• Showcased the potential for noninvasive biomarkers to differentiate disease severity and guide treatment.

Conclusions:

• Noninvasive peripheral blood biomarkers hold significant promise for refining acute GVHD diagnosis and management after HCT.
• Emerging biomarkers like elafin and reg3α, alongside cytokines, offer new avenues for predicting outcomes.
• Future applications include differential and pre-emptive therapies based on biomarker profiles to improve patient outcomes.